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Background 
Of the 55,000 women diagnosed with breast cancer1 each year, over 40% will require a 
mastectomy2 as primary surgical treatment.  In efforts to optimise quality of life and 
outcomes, the National Institute for Health and Care Excellence (NICE) recommend offering 
immediate breast reconstruction3.  In the UK4 and US5, implant-based breast reconstruction 
(IBBR) is the most commonly-performed technique.   
The earliest approach to IBBR was to place the implant directly under the skin flaps in a 
subcutaneous position.  This was abandoned because of unacceptably high complication 
rates6 and instead, the implant is usually placed in a pocket under the pectoralis major 
muscle.  This generally requires a two-stage approach as the initial pocket is not large 
enough to accommodate a fixed-volume implant so a tissue-expander is placed as a first 
stage.  Multiple expansions (by injecting fluid percutaneously) are required until the desired 
size is achieved. The expander is then replaced by a fixed-volume implant at a second 
operation.  This technique is safe, but time-consuming and uncomfortable.  
The introduction of biological and synthetic meshes to augment the submuscular pocket has 
a major impact on the practice of IBBR.  The mesh can be used as a sling between the lower 
edge of pectoralis muscle and the chest wall to provide coverage for the lower pole of the 
implant. This creates a much bigger submuscular pocket (figure 1) and allows a single-stage 
procedure to be performed with the definitive and right sized implant placed at the time of 
mastectomy.  It is thought that cosmetic outcomes are improved due to better lower pole 
projection and improved control of the inframammary fold which creates a more ptotic 
natural-looking result.  A wide range of biological (e.g. acellular dermal matrix, ADM) and 
synthetic (e.g titanium coated polypropylene) meshes are available.  These differ in cost 
(£300 to £2000) and in the absence of comparative evidence, usage is currently dependent 
on surgeon preference.   
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Recently, practice has evolved. Surgeons may place the implant, fully or partially wrapped in 
mesh, on top of the pectoralis muscle in a subcutaneous position (figure 1).  It is suggested 
that the subcutaneous technique may reduce post-operative pain as the muscle is not 
disturbed.  Implant ‘animation’, the distressing upwards movement of the implant that is seen 
when the chest muscles contract in standard submuscular techniques is also avoided6.     
It is unclear, however, whether mesh-assisted procedures are a safe alternative to traditional 
IBBR techniques and if patient-reported and cosmetic outcomes are improved when mesh is 
used.  It is unclear which type of mesh (biological or synthetic) should be used. There is also 
uncertainty about the best position for the implant when a mesh is used (under the skin or 
under the muscle).    
What is the evidence of uncertainty? 
We searched PubMed, the Cochrane Library and the clinicaltrials.gov databases to identify 
published and ongoing randomised clinical trials (RCTs) and systematic reviews that 
evaluated mesh in women undergoing IBBR following mastectomy for breast cancer or risk-
reduction. 
Mesh vs. no mesh  
A 2015 systematic review evaluated the published evidence for ADM in IBBR7.  This 
included 8 systematic reviews; 1 RCT; 40 non-randomised comparative studies and 20 
case-series.  The review concluded that current evidence was limited, and further research 
was required but no meta-analysis was performed due to the heterogeneity of the included 
studies.  A more recent systematic review8 9 included 28 non-randomised studies and 23 
case-series reporting the outcomes of biological and synthetic meshes.  Several meta-
analyses were performed to compare overall complications and specific clinical outcomes 
including implant loss, infection and capsular contracture in patients undergoing IBBR with 
and without mesh.  Pooled analysis suggested a higher rate of infection in the mesh-assisted 
group (risk ratio 1.55, 95% confidence intervals 1.17-2.05) but no other significant 
 4 
 
differences in complications when mesh was used, but the quality of the included studies 
was low8.  It concluded that data, in particular relating to health-related quality of life and 
oncological outcomes were lacking and that RCTs were ‘urgently needed’9.    
Since the completion of these reviews, a multicentre Dutch RCT comparing quality of life, 
safety and cosmetic outcomes in single-stage direct-to-implant IBBR with ADM and 
traditional two-stage expander-implant reconstruction has reported10 (table 1).  To date, only 
safety data at one year are published but patients in the ADM group experienced 
significantly more surgical complications (odds ratio 3.46, 95% confidence interval 1.39-
8.61), complications requiring re-operation (odds ratio 3.69, 95% confidence interval 1.31-
10.42) and a higher incidence of reconstructive failure (odds ratio 16.82, 95% confidence 
interval 2.44-115.94) than those undergoing two-stage expander-implant reconstruction.  
While these results are concerning, the study is small (n=142) and at high risk of bias due to 
lack of blinding of outcome assessors.  Importantly, it did not take account of the learning 
curve of participating surgeons11 which has been shown to significantly impact on surgical 
complications in ADM-assisted IBBR12.   
A multicentre prospective North American cohort study13 has recently compared 
complications and patient-reported outcomes in 1297 women undergoing two-stage IBBR 
with and without ADM.  Complications were defined as adverse, surgery-related post-
operative events requiring additional treatment at 2 years following expander placement.  
The incidence of any complication, major complications requiring re-operation or 
readmission to hospital and reconstructive failure (removal of the implant) was compared 
between the procedure groups and patient-reported outcomes were assessed pre-
operatively and at 1 week, three months, one and two years post-operatively using the 
validated BREAST-Q questionnaire. There were no significant differences in the clinical or 
patient-reported outcomes between the two groups.  Although this is an interesting study 
that provides data on the two-stage approach, this is not standard practice in the UK.  There 
also remains the need to evaluate it within the context of a randomised study.    
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Type of mesh: biological or synthetic? 
The 2015 systematic review7 included nine non-randomised studies comparing different 
types of ADM. These were small, retrospective, mostly single-centre reports and the findings 
of no differences between products are of limited value 
An updated literature review has identified two small single-centre RCTs comparing 
complications of different human ADMs14 15 and have demonstrated no significant 
differences in outcomes between different products (table 1).  These studies were not 
reported in sufficient detail for the risk of bias to be formally assessed, but as the trials were 
largely explanatory, the results are unlikely to be generalisable.  A third small pilot RCT 
compared biological and synthetic meshes16.  This study compared cosmetic outcomes 
using panel photographic assessment, complications and quality of life using the EORTC 
QLQ C30 and BR23 questionnaires in patients receiving biological and synthetic mesh.  
There were no significant differences in cosmetic outcome and overall complications 
between the patient groups, but patients in the ADM group experienced significantly higher 
rates of implant loss than those undergoing IBBR with synthetic mesh (n=7 vs. n=2, 
P<0.0001).  Patients in the ADM group also reported more post-operative pain, more fatigue 
and more disruption to their family life than those in the synthetic mesh group.  Although 
reported as a ‘pilot’ trial, this study is a small trial that is insufficiently well-designed to look at 
the target different between the treatment groups17.  No primary outcome or power 
calculation are reported and there are insufficient details to allow the risk of bias to be 
formally assessed.  This study therefore represents very low quality evidence the results of 
which cannot be relied upon (table 1).   
Subcutaneous vs. submuscular implant reconstruction with mesh 
Our updated search did not identify any RCTs or systematic reviews in this field. Just one 
narrative review was found6.  This includes case-series with few studies directly comparing 
submuscular and subcutaneous techniques.   
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Is ongoing research likely to provide relevant evidence? 
Searches of ClinicalTrials.gov; the ISRCTN registry and the Cochrane Library identified 
several small ongoing randomised trials; two multicentre studies comparing two-stage 
expander-implant and single-stage direct-to-implant reconstruction with ADM in Europe 
(NCT02061527,n=120) and Canada (NCT00956384,n=189) and five further studies 
comparing meshes; three comparing human (NCT03145337;NCT02891759) and non-
human ADMs (NCT02521623;n=60)  and three comparing biological and synthetic mesh in 
submuscular (NCT02985073;n=40) and subcutaneous (NCT02830685; NCT02831426) 
IBBR.  A single small study (NCT03143335) was identified comparing subcutaneous and 
subpectoral techniques. 
While these trials will add to the evidence-base, they are unlikely to be sufficiently large or 
pragmatic to definitely determine whether mesh is safe or if it improves patient-reported and 
cosmetic outcomes in IBBR; which mesh should be used or where the implant should be 
placed.    
The iBRA study (ISRCTN37664281) is a non-randomised prospective multicentre cohort 
study which aims to inform the feasibility, design and conduct of a pragmatic RCT in IBBR18.   
iBRA will provide important data for hypothesis generation and it will inform an efficient and 
acceptable trial design. It is also serving as an important process of establishing networks 
and demonstrating how plastic and breast surgeons can work together.  
What should we do in light of this uncertainty? 
In light of the lack of evidence and recent issues with other mesh-based procedures19, 
surgeons and specialist nurses involved in breast reconstruction decision-making should 
ensure that patients are fully-informed that there is limited short and long-term safety and 
patient-reported outcome data for mesh-assisted IBBR  and that surgeons may have limited 
experience with the technique.  As large numbers of women are electing to undergo these 
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procedures, the degree to this information is currently shared with patients is unknown, 
raising questions about the quality of information provision and informed consent. 
Published guidelines20 21 are largely based on poor-quality evidence and expert opinion but 
offer sensible advice regarding current best practice.  The American Society of Plastic 
Surgeons recommend that mesh use should be considered on a per-patient basis20.  Careful 
patient selection and performing mesh-assisted IBBR with caution in high-risk groups (such 
as current smokers, patients who have had previous breast radiotherapy, and those with a 
high BMI) is recommended by the UK professional associations, the Association of Breast 
Surgery (ABS) and the British Association of Plastic, Reconstructive and Aesthetic 
Surgeons21 together with robust prospective audit of surgical outcomes to generate data to 
support practice.   
New techniques and devices in breast reconstruction require evaluation.  Surgeons need to 
embrace the concept of ‘no innovation without evaluation’ and commit to only performing 
new techniques within the context of well-designed protocolled early-phase evaluation 
studies or registries using standardised outcomes measures. Equally it is possible that 
governance structures for surgical innovation need to change. 
RCTs in IBBR are urgently-needed and notoriously challenging but careful feasibility work 
may be the key to successful future trials.  Patients and the reconstructive community need 
to work together to design and conduct multicentre, pragmatic studies that will provide much-
needed evidence to determine the best and most cost-effective approach to IBBR.  
Recommendations for further research 
Population: Women aged 16 or over undergoing mastectomy for breast cancer or risk-
reduction electing to undergo immediate implant-based breast reconstruction 
Intervention and comparisons: The key question is whether ADM improves the outcome of 
implant-based breast reconstruction but there is also a need to determine which type of 
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mesh and where the implant should be placed.  It may be possible to address the 
questions within a single trial with an adaptive or factorial design. 
i) Single-stage direct-to-implant reconstruction with mesh vs standard two-stage 
expander-implant reconstruction 
ii) Biological vs synthetic mesh 
iii) Subcutaneous vs submuscular implant reconstruction with mesh 
Outcome: Patient-centred outcomes including patient satisfaction although safety 
outcomes such as rates of implant loss will be important, and the use of the breast 
reconstruction core outcome set22 would be recommended.  Adequate follow up and 
appropriate timing of outcome assessment will essential to understand the final cosmetic 
result achieved and robust economic evaluation will be an important component of any 
future trial. 
 
What you need to know 
Implant-based breast reconstruction is the most commonly performed procedure in the UK 
and US 
The use of biological and synthetic meshes in implant-based reconstruction has become 
standard care, but there is limited high-quality evidence to support their safety or 
effectiveness. 
Surgeons performing breast reconstruction need to work together to generate evidence to 
support practice.  
 
How patients were involved in the creation of this article 
A patient advocate is a co-author of this article and patients are involved on the steering 
group of our ongoing IBBR studies. 
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They expressed concerns that patients are unaware of the degree of uncertainty 
surrounding the use of mesh and that it is difficult for patients to get clear advice on what 
approach would be right for them. 
We have ensured that the ‘what patients need to know’ box includes questions for patients 
to ask their surgeon which may help them make more informed decisions about their 
options. 
 
What patients need to know 
Surgeons offering mesh-assisted implant-based breast reconstruction should explain to 
patients that although we believe that mesh may improve patient satisfaction and cosmetic 
outcome, there is no good published research to support this.   
Surgeons should explain that the short-term complications of mesh-assisted procedures 
may be higher than traditional implant-reconstruction and that we don’t currently 
understand the long-term outcomes of mesh-procedures including the need for further 
surgery over time. 
Surgeons should be able to share their personal complication rates in particular how many 
patients need a second operation for complications and how many patients need their 
implant removed, why this may be needed and when it may occur to help patients make 
more informed decisions about surgery. 
Surgeons should be transparent and honest if they are trying a new technique such as 
placing the implant under the skin for the first time and allow patients to decide whether or 
not they would like to choose this option. 
Surgeons should encourage patients electing to undergo mesh-assisted procedures to 
take part in research studies to address some of these uncertainties. 
 
Education into practice 
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Do you mention the lack of evidence for the use of mesh in your discussions with patients 
considering implant-based breast reconstruction? 
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Table 1 – Summary of randomised clinical trials evaluating mesh use in implant-based breast reconstruction 
RCTs comparing implant-based breast reconstruction with and without mesh 
Study Sample 
size 
Intervention Comparison Outcomes assessed Main findings Quality of 
evidencea 
Uncertainty 
McCarthy et al, 
2012 
69 
 
2 stage 
expander-
implant 
reconstruction 
with human ADM 
(AlloDerm) 
n=33 
Standard 2 stage 
expander-
implant 
reconstruction 
n=36 
i. Pain using BREAST-Q 
Physical well-being Chest 
and Upper Body Scale 
and VAS post-operatively 
and during expansion 
phase 
ii. Rate of tissue expansion 
No differences in pain post-operatively or during the 
expansion period.  No differences in rate of post-
operative expansion 
Moderate Underpowered - Study stopped by Data Safety Monitoring 
Board due to concerns about recruitment. 
Use of human ADM in 2 stage expander-implant 
reconstruction does not reflect UK practice 
Dikmans et al, 
2016  
142 Single-stage 
direct to implant 
reconstruction 
with porcine 
ADM (Strattice) 
n=59 
Standard 2 stage 
expander-
implant 
reconstruction 
n=62 
i. HRQL assessed using the 
BREAST-Q and EQ-5D at 
1 year 
ii. Safety – adverse events 
classified using CTCAE 
criteria at 1 year 
iii. Aesthetic outcomes based 
on photographs at 1 year 
Significantly higher rates of surgical complications 
(OR 3.46, 95% CI 1.39-8.61); re-operation (OR 3.69, 
95% CI 1.31-10.42) and removal of implant (OR 
16.82, 95% CI 2.44-115.94) in patients undergoing 
single stage reconstruction with ADM compared with 
2 stage expander-implant procedures without ADM. 
HRQL and aesthetic outcomes not reported.   
Very low Very selected patient population (non-smokers, BMI<30, 
no post-mastectomy radiotherapy, small breasts) 
High risk of bias due to lack of blinding  
Failed to account for surgeons’ learning curve with new 
technique  
Two surgeon model (oncologic surgeon performing 
mastectomy and plastic surgeon performing 
reconstruction) not consistent with UK practice. 
RCTs comparing different types of mesh 
Study Sample 
size 
Intervention Comparison Outcomes assessed Main findings Quality of 
evidencea 
Uncertainty 
Mendenhall et 
al, 2015 
116 2 stage 
expander-
implant 
reconstruction 
with human ADM 
(DermaMatrix) 
n=59 
2 stage 
expander-
implant 
reconstruction 
with human ADM 
(AlloDerm)  
n=57 
i. Incidence and grade of 
complications 
ii. Expander dynamics 
iii. Biointegration of ADM 
No difference in overall complications (OR 1.24, 95% 
CI 0.64-2.40) or grade of complications (OR 1.33, 
95% CI 0.75-2.35) between treatment groups.  
AlloDerm resulted in less time to complete expansion 
(42 vs 72 days, p<0.001).   
Low All procedures performed by single surgeon so not 
generalisable.   
High risk of bias due to method of allocation concealment 
(sealed envelopes).  No reported blinding of outcome 
assessors  
Use of human ADM in 2 stage expander-implant 
reconstruction does not reflect UK practice 
Gschwantler-
Kaulich et al, 
2016 
48 Single stage 
direct to implant 
with porcine 
ADM (Protexa) 
n=23 
Single stage 
direct to implant 
with synthetic 
mesh (TiLOOP) 
n=25 
i. Cosmetic outcome 
assessed from 
photographs 
ii. Complications 
iii. HRQL assessed using 
EORTC QLQ C30 and 
BR23 
No significant difference in overall complications 
between patient groups (31.3% ADM, 24.0% 
TiLOOP, p=0.19) but significantly higher rate of 
implant loss and reconstructive failure in the ADM 
group (30.4% vs 7.7%, p<0.0001). 
Patients in ADM group reported significantly more 
arm pain (48% vs. 24%, p=0.04) and fatigue (35% vs 
12%, p=0.03) at the first post-operative visit and a 
more affected family life (17% vs 0%, p=0.02) and 
less sexual interest (17% vs 48%) at 6 months 
following reconstruction. 
There was no difference in cosmetic outcome. 
Very low Reported as ‘pilot’ RCT but no feasibility endpoints 
assessed. 
Underpowered trial.   
No primary endpoint identified; no power calculation 
performed 
Insufficient details reported to assess risk of bias. 
HRQL instruments not validated in BR population 
ADM assessed not routinely used in UK 
Hinchcliff et al, 
2017 
30 2 stage 
expander-
implant 
reconstruction 
with human ADM 
(AlloMaxTM) 
n=15 
2 stage 
expander-
implant 
reconstruction 
with human ADM 
(AlloDerm)  
n=15 
i. Complication rate 
ii. Patient satisfaction at 1 
year using BRECON-31 
questionnaire 
No significant difference in complications between 
patient groups at 30 days or following implant 
exchange  
Very low All procedures performed by single surgeon so not 
generalisable.   
Very small sample size 
Insufficient details reported to formally assess risk of bias 
Use of human ADM in 2 stage expander-implant 
reconstruction does not reflect UK practice 
ausing GRADE; ADM – acellular dermal matrix; CI – confidence interval; CTCAE – Common Terminology Criteria for Adverse Events (version 4.0), EORTC – European Organisation for Research and Treatment of Cancer; HRQL – 
health-related quality of life; OR – odds ratio; UK – United Kingdom, VAS – visual analogue scale. 
 
